|
1
|
Monzon FA, Ogino S, Hammond ME, Halling
KC, Bloom KJ and Nikiforova MN: The role of KRAS mutation testing
in the management of patients with metastatic colorectal cancer.
Arch Pathol Lab Med. 133:1600–1606. 2009.PubMed/NCBI
|
|
2
|
Brozovic A, Fritz G, Christmann M,
Zisowsky J, Jaehde U, Osmak M and Kaina B: Long-term activation of
SAPK/JNK, p38 kinase and Fas-L expression by cisplatin is
attenuated in human carcinoma cells that acquired drug resistance.
Int J Cancer. 112:974–985. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sánchez-Perez I, Murguía JR and Perona R:
Cisplatin induces a persistent activation of JNK that is related to
cell death. Oncogene. 16:533–540. 1998.PubMed/NCBI
|
|
4
|
Liu LZ, Zhou XD, Qian G, Shi X, Fang J and
Jiang BH: AKT1 amplification regulates cisplatin resistance in
human lung cancer cells through the mammalian target of
rapamycin/p70S6K1 pathway. Cancer Res. 67:6325–6332. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Toker A and Yoeli-Lerner M: Akt signaling
and cancer: surviving but not moving on. Cancer Res. 66:3963–3966.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bellacosa A, Kumar CC, Di Cristofano A and
Testa JR: Activation of AKT kinases in cancer: implications for
therapeutic targeting. Adv Cancer Res. 94:29–86. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deng R, Tang J, Xie BF, Feng GK, Huang YH,
Liu ZC and Zhu XF: SYUNZ-16, a newly synthesized alkannin
derivative, induces tumor cells apoptosis and suppresses tumor
growth through inhibition of PKB/AKT kinase activity and blockade
of AKT/FOXO signal pathway. Int J Cancer. 127:220–229. 2010.
View Article : Google Scholar
|
|
9
|
Yu HG, Ai YW, Yu LL, Zhou XD, Liu J, Li
JH, Xu XM, Liu S, Chen J, Liu F, et al: Phosphoinositide
3-kinase/Akt pathway plays an important role in chemoresistance of
gastric cancer cells against etoposide and doxorubicin induced cell
death. Int J Cancer. 122:433–443. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang X, Fraser M, Moll UM, Basak A and
Tsang BK: Akt-mediated cisplatin resistance in ovarian cancer:
modulation of p53 action on caspase-dependent mitochondrial death
pathway. Cancer Res. 66:3126–3136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fraser M, Leung BM, Yan X, Dan HC, Cheng
JQ and Tsang BK: p53 is a determinant of X-linked inhibitor of
apoptosis protein/Akt-mediated chemoresistance in human ovarian
cancer cells. Cancer Res. 63:7081–7088. 2003.PubMed/NCBI
|
|
12
|
Pellegrini S and Dusanter-Fourt I: The
structure, regulation and function of the Janus kinases (JAKs) and
the signal transducers and activators of transcription (STATs). Eur
J Biochem. 248:615–633. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun J, Blaskovich MA, Jove R, Livingston
SK, Coppola D and Sebti SM: Cucurbitacin Q: a selective STAT3
activation inhibitor with potent antitumor activity. Oncogene.
24:3236–3245. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Martindale JL and Holbrook NJ: Cellular
response to oxidative stress: signaling for suicide and survival. J
Cell Physiol. 192:1–15. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park S, Kim D, Kaneko S, Szewczyk KM,
Nicosia SV, Yu H, Jove R and Cheng JQ: Molecular cloning and
characterization of the human AKT1 promoter uncovers its
up-regulation by the Src/Stat3 pathway. J Biol Chem.
280:38932–38941. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee BL, Lee HS, Jung J, Cho SJ, Chung HY,
Kim WH, Jin YW, Kim CS and Nam SY: Nuclear factor-kappaB activation
correlates with better prognosis and Akt activation in human
gastric cancer. Clin Cancer Res. 11:2518–2525. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Testa JR and Bellacosa A: AKT plays a
central role in tumorigenesis. Proc Natl Acad Sci U S A.
98:10983–10985. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ruggero D and Sonenberg N: The Akt of
translational control. Oncogene. 24:7426–7434. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim D, Dan HC, Park S, Yang L, Liu Q,
Kaneko S, Ning J, He L, Yang H, Sun M, et al: AKT/PKB signaling
mechanisms in cancer and chemoresistance. Front Biosci. 10:975–987.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang HL, Fang LW, Lu SP, Chou CK, Luh TY
and Lai MZ: DNA-damaging reagents induce apoptosis through reactive
oxygen species-dependent Fas aggregation. Oncogene. 22:8168–8177.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Antico Arciuch VG, Galli S, Franco MC, Lam
PY, Cadenas E, Carreras MC and Poderoso JJ: Akt1 intramitochondrial
cycling is a crucial step in the redox modulation of cell cycle
progression. PLoS One. 4:e75232009.PubMed/NCBI
|
|
22
|
Carpten JD, Faber AL, Horn C, Donoho GP,
Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage
S, et al: A transforming mutation in the pleckstrin homology domain
of AKT1 in cancer. Nature. 448:439–444. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu X, Shi Y, Han EK, Chen Z, Rosenberg
SH, Giranda VL, Luo Y and Ng SC: Down regulation of Akt1 inhibits
anchorage-independent cell growth and induces apoptosis in cancer
cells. Neoplasia. 3:278–286. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Real PJ, Sierra A, De Juan A, Segovia JC,
Lopez-Vega JM and Fernandez-Luna JL: Resistance to chemotherapy via
Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer
cells. Oncogene. 21:7611–7618. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Garcia R, Bowman TL, Niu G, Yu H, Minton
S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, et
al: Constitutive activation of Stat3 by the Src and JAK tyrosine
kinases participates in growth regulation of human breast carcinoma
cells. Oncogene. 20:2499–2513. 2001. View Article : Google Scholar : PubMed/NCBI
|
